United Therapeutics
UTHR
383 hedge funds and large institutions have $8.87B invested in United Therapeutics in 2015 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 132 increasing their positions, 138 reducing their positions, and 49 closing their positions.
62% more call options, than puts
Call options by funds: $64.9M | Put options by funds: $40M
43% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 49
5% more funds holding
Funds holding: 366 → 383 (+17)
2% less capital invested
Capital invested by funds: $9.02B → $8.87B (-$146M)
4% less repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 138
33% less funds holding in top 10
Funds holding in top 10: 15 → 10 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$92.2M |
| 2 |
Renaissance Technologies
New York
|
+$65.7M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$59M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$57.9M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$56.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TimesSquare Capital Management
New York
|
-$140M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$134M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$116M |
| 4 |
YCMGA
York Capital Management Global Advisors
New York
|
-$64.2M |
| 5 |
CCM
Consonance Capital Management
New York
|
-$58.5M |
UTHR Hedge Fund Activity: Q2 2015 in Review
383 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q2 2015, worth a combined $8.87B — down 1.6% from $9.02B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new UTHR positions and 49 closed out — a net gain of 21 holders — while 132 added to existing stakes and 138 trimmed.
The largest buyer was Putnam Investments, adding an estimated $92.2M. The largest seller was TimesSquare Capital Management, cutting an estimated $140M.
- 383 institutional investors held United Therapeutics (UTHR) as of Q2 2015, up from 366 in Q1 2015.
- Funds reported $8.87B of United Therapeutics stock for Q2 2015, down 1.6% quarter-over-quarter.
- 70 funds opened new United Therapeutics positions in Q2 2015 and 49 closed out, a net change of +21 holders.
- The largest United Therapeutics buyer in Q2 2015 was Putnam Investments, an estimated $92.2M added.
- The largest United Therapeutics seller in Q2 2015 was TimesSquare Capital Management, an estimated $140M sold.
Based on aggregated 13F filings for Q2 2015.